What's New in 2024

This page summarizes substantive changes to the traditional MIPS program as they apply to optometry and ophthalmology. The information presented here is not intended to be comprehensive. Refer to the individual measure topics for specifics. Here's what's new this performance year:

  • Data completeness has been increased from 70% to 75%. This means you must report at least 75% of eligible encounters for each measure, regardless of payer to receive at least 3 points for each measure.
  • The age requirement has been lowered from 18 to 12 for measure 226. Preventive Care and Screening: Tobacco Use: Screening and Cessation Intervention.
  • The IOP reduction threshhold increased from 15% to 20% for measure 141. Primary Open-Angle Glaucoma (POAG): Reduction of Intraocular Pressure (IOP) by 20% or Documentation of a Plan of Care.
  • The codes used to meet 117. Diabetes: Eye Exam have changed:
    • 2022F is now M1220, "dilated retinal eye exam with interpretation by an ophthalmologist or optometrist or artificial intelligence (AI) interpretation documented and reviewed; with evidence of retinopathy."
    • 2023F is now M1221, "Dilated retinal eye exam with interpretation by an ophthalmologist or optometrist or artificial intelligence (AI) interpretation documented and reviewed; without evidence of retinopathy."
  • CMS retired the following Quality measures:
  • Eyefinity removed the following Quality measures from the Eyefinity EHR built-in registry:
    • 191. Cataracts: 20/40 or Better Visual Acuity within 90 Days Following Cataract Surgery
    • 374. Closing the Referral Loop: Receipt of Specialist Report
  • The PI performance period increases from 90 days to 180 days. This means you will need to report six months of Promoting Interoperability data. This change is intended to produce more comprehensive and reliable data without increasing clinician burden.
  • The High Priority Practices Guide of the Safety Assurance Factors for EHR Resilience (SAFER) Guides measure now requires a YES attestation. Attesting NO will result in a score of Zero for the entire PI category. Previously, you could attest Yes or No and received credit for the PI category.
  • The Query of Prescription Drug Monitoring Program (PDMP) measure now includes an exclusion for any clinician who does not prescribe any Schedule II opioids or Schedule III or IV drugs during the performance period.
  • CMS added five new Cost measures, but none apply to eyecare.